Protalix BioTherapeutics, Inc. Gross Profit

• Protalix BioTherapeutics, Inc. showed an increase of +400.7% in Gross Profit from 2016 to 2017.
• This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2018.
• XBRL data for this metric is available from 2009 to 2017 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2010: $613.0 thousand | Q3 2010: $2.12 million | Q1 2011: $5.22 million | Q2 2011: -$4.75 million | Q3 2011: $677.0 thousand | Q1 2012: $2.41 million | Q2 2012: $21.98 million | Q3 2012: $3.02 million | Q1 2013: $3.00 million | Q2 2013: $1.75 million | Q3 2013: $1.77 million | Q1 2014: $3.31 million | Q2 2014: $1.08 million | Q3 2014: $1.91 million | Q1 2015: $1.41 million | Q2 2015: $1.11 million | Q3 2015: $1.11 million | Q1 2016: $156.0 thousand | Q2 2016: $94.0 thousand | Q3 2016: $422.0 thousand | Q1 2017: $801.0 thousand | Q2 2017: $835.0 thousand | Q3 2017: $1.46 million | Q1 2018: $1.63 million | Q2 2018: -$177.0 thousand | Q3 2018: -$1.25 million.
• Over the full 9 years of available data (2009 to 2017), Protalix BioTherapeutics, Inc.'s Gross Profit has grown by 225.9%.
• Historical annual values: Fiscal year 2017: $4.01 million | Fiscal year 2016: $801.0 thousand | Fiscal year 2015: $3.63 million | Fiscal year 2014: $2.89 million | Fiscal year 2013: $0.00 | Fiscal year 2012: $26.28 million | Fiscal year 2011: $1.44 million | Fiscal year 2010: $6.86 million | Fiscal year 2009: -$3.19 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026